Chemokine CX3CL1 (Fractalkine) Signaling and Diabetic Encephalopathy

Area of Science:

• Neuroscience
• Endocrinology
• Immunology

Background:

• Diabetes mellitus (DM) is a global epidemic linked to obesity, leading to hyperglycemia and systemic complications.
• Diabetic encephalopathy (DE) is a CNS complication of DM, causing cognitive and motor deficits, driven by oxidative stress and neuroinflammation.
• The fractalkine (CX3CL1) and its receptor CX3CR1 play a dual role in neuroinflammation, modulating microglial activity.

Purpose of the Study:

• To review the dual role of the CX3CL1-CX3CR1 signaling axis in diabetic encephalopathy (DE).
• To explore the potential of targeting this pathway for therapeutic intervention in DE.
• To emphasize the importance of glycemic control in preventing DE.

Main Methods:

• Literature review of studies investigating CX3CL1-CX3CR1 signaling in the context of diabetes and neurological disorders.
• Analysis of evidence for both neuroprotective and neurotoxic effects of CX3CL1-CX3CR1 signaling.
• Discussion of the implications for therapeutic strategies in DE.

Main Results:

• The CX3CL1-CX3CR1 pathway exhibits context-dependent effects, acting as both a neuroprotective and neurotoxic mediator in DE.
• Evidence suggests this signaling axis influences microglial activation and inflammatory responses in the CNS.
• Interrupting detrimental neuron-microglia interactions via CX3CL1-CX3CR1 modulation is a potential therapeutic avenue.

Conclusions:

• The CX3CL1-CX3CR1 axis presents a complex therapeutic target for diabetic encephalopathy.
• Modulating this pathway could mitigate neuroinflammation and neurotoxicity in DE.
• Optimal prevention of DE remains centered on stringent glycemic control to eliminate underlying hyperglycemic conditions.